Refining Treatment Options for Trichomonas Vaginalis Infection: A Comparative Analysis of Metronidazole and Secnidazole

PHASE4RecruitingINTERVENTIONAL
Enrollment

1,200

Participants

Timeline

Start Date

May 6, 2025

Primary Completion Date

May 1, 2029

Study Completion Date

July 31, 2029

Conditions
Trichomonas VaginitisBacterial Vaginitis
Interventions
DRUG

Metronidazole 500 mg

Multi-dose oral MTZ (500 mg twice daily for 7 days) for the treatment of T. vaginalis infection in women and men

DRUG

Secnidazole 2000 MG

Single-dose 2 g oral SEC for the treatment of T. vaginalis infection in women and men

Trial Locations (4)

25233

RECRUITING

University of Alabama at Birmingham [UAB] Gynecology Clinics, Birmingham

33161

NOT_YET_RECRUITING

Segal Trials Healthcare Clinical Data, Inc. 1065 NE 125th St. Suite 417 North Miami, FL 33161, North Miami

35205

RECRUITING

UAB Sexual Health Research Clinic [SHRC], Birmingham

70119

RECRUITING

LSU-CrescentCare Sexual Health Center, New Orleans

All Listed Sponsors
collaborator

University of Alabama at Birmingham

OTHER

collaborator

Louisiana State University Health Sciences Center in New Orleans

OTHER

collaborator

Segal Trials Healthcare Clinical Data, Inc

UNKNOWN

lead

Tulane University

OTHER

NCT06261840 - Refining Treatment Options for Trichomonas Vaginalis Infection: A Comparative Analysis of Metronidazole and Secnidazole | Biotech Hunter | Biotech Hunter